Pulmonary Delivery of Aerosolized Chloroquine and Hydroxychloroquine to Treat COVID-19: In Vitro Experimentation to Human Dosing Predictions
暂无分享,去创建一个
M. Peitsch | J. Hoeng | N. Ivanov | A. Kuczaj | P. Guy | S. Frentzel | S. Majeed | A. Kolli | Tanja Živković Semren | D. Bovard | M. van der Toorn | Sophie Scheuner | A. Mazurov | Florian Calvino-Martin | J. O'mullane | Philippe A Guy | Shoaib Majeed
[1] H. Boushey,et al. Phase 1 Randomized Placebo-Controlled Study in Healthy Adult Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate – A Potential Treatment for COVID-19 , 2021, Journal of Allergy and Clinical Immunology.
[2] A. Calise,et al. Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study , 2020, BMC Infectious Diseases.
[3] W. Jusko,et al. Physiologically Based Pharmacokinetics of Lysosomotropic Chloroquine in Rat and Human , 2020, The Journal of Pharmacology and Experimental Therapeutics.
[4] H. Kerstjens,et al. Tolerability and pharmacokinetic evaluation of inhaled dry powder hydroxychloroquine in healthy volunteers , 2020, medRxiv.
[5] D. Concordet,et al. Hydroxychloroquine lung pharmacokinetics in critically ill patients with COVID-19 , 2020, International Journal of Antimicrobial Agents.
[6] P. Lienau,et al. Extension of the Mechanistic Tissue Distribution Model of Rodgers and Rowland by Systematic Incorporation of Lysosomal Trapping: Impact on Unbound Partition Coefficient and Volume of Distribution Predictions in the Rat , 2020, Drug Metabolism and Disposition.
[7] W. Haefeli,et al. Interaction of Hydroxychloroquine with Pharmacokinetically Important Drug Transporters , 2020, Pharmaceutics.
[8] E. Goetghebeur,et al. Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants , 2020, International Journal of Antimicrobial Agents.
[9] M. Müller,et al. Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2 , 2020, Nature.
[10] P. Bhargava,et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19 , 2020, International Journal of Infectious Diseases.
[11] C. Yao,et al. SARS-CoV-2 infection of primary human lung epithelium for COVID-19 modeling and drug discovery , 2020, bioRxiv.
[12] V. Calvez,et al. Compassionate use of hydroxychloroquine in clinical practice for patients with mild to severe Covid-19 in a French university hospital , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] K. Rowland Yeo,et al. Impact of Disease on Plasma and Lung Exposure of Chloroquine, Hydroxychloroquine and Azithromycin: Application of PBPK Modeling , 2020, Clinical pharmacology and therapeutics.
[14] Jiang Liu,et al. Connecting hydroxychloroquine in vitro antiviral activity to in vivo concentration for prediction of antiviral effect: a critical step in treating COVID-19 patients , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] H. Derendorf. Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin , 2020, International Journal of Antimicrobial Agents.
[16] Fabian J Theis,et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes , 2020, Nature Medicine.
[17] J. Qiao,et al. Dose selection of chloroquine phosphate for treatment of COVID-19 based on a physiologically based pharmacokinetic model , 2020, Acta Pharmaceutica Sinica B.
[18] Susan Daniel,et al. Coronavirus membrane fusion mechanism offers a potential target for antiviral development , 2020, Antiviral Research.
[19] Q. Bassat,et al. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. , 2020, JAMA network open.
[20] A. Kalil. Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics. , 2020, JAMA.
[21] Zhìhóng Hú,et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro , 2020, Cell Discovery.
[22] Xu Liu,et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] Gengfu Xiao,et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.
[24] M. Peitsch,et al. Bridging inhaled aerosol dosimetry to physiologically based pharmacokinetic modeling for toxicological assessment: nicotine delivery systems and beyond , 2019, Critical reviews in toxicology.
[25] R. Irizarry. ggplot2 , 2019, Introduction to Data Science.
[26] M. Peitsch,et al. Application of a multi-layer systems toxicology framework for in vitro assessment of the biological effects of Classic Tobacco e-liquid and its corresponding aerosol using an e-cigarette device with MESH™ technology , 2019, Archives of Toxicology.
[27] M. Brodlie,et al. Real-Time, Semi-Automated Fluorescent Measurement of the Airway Surface Liquid pH of Primary Human Airway Epithelial Cells , 2019, Journal of visualized experiments : JoVE.
[28] Luo Zhang,et al. Influence of Intranasal Drugs on Human Nasal Mucociliary Clearance and Ciliary Beat Frequency , 2018, Allergy, asthma & immunology research.
[29] Julia Hoeng,et al. A lung/liver-on-a-chip platform for acute and chronic toxicity studies. , 2018, Lab on a chip.
[30] D. Gustafson,et al. Hydroxychloroquine: A Physiologically-Based Pharmacokinetic Model in the Context of Cancer-Related Autophagy Modulation , 2018, The Journal of Pharmacology and Experimental Therapeutics.
[31] D. Oupický,et al. Simultaneous quantitation of hydroxychloroquine and its metabolites in mouse blood and tissues using LC-ESI-MS/MS: An application for pharmacokinetic studies. , 2018, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[32] Aleksandra Galetin,et al. Incorporation of lysosomal sequestration in the mechanistic model for prediction of tissue distribution of basic drugs , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[33] Michael Gertz,et al. In Vitro and in Silico Tools To Assess Extent of Cellular Uptake and Lysosomal Sequestration of Respiratory Drugs in Human Alveolar Macrophages. , 2017, Molecular pharmaceutics.
[34] Eleonore Fröhlich,et al. Measurements of Deposition, Lung Surface Area and Lung Fluid for Simulation of Inhaled Compounds , 2016, Front. Pharmacol..
[35] M. Jamei,et al. A Bottom-Up Whole-Body Physiologically Based Pharmacokinetic Model to Mechanistically Predict Tissue Distribution and the Rate of Subcutaneous Absorption of Therapeutic Proteins , 2015, The AAPS Journal.
[36] M. Bolognesi,et al. Lewis Acid‐Catalyzed Generation of CC and CN Bonds on π‐Deficient Heterocyclic Substrates , 2015 .
[37] Bahman Asgharian,et al. Thoracic and respirable particle definitions for human health risk assessment , 2013, Particle and Fibre Toxicology.
[38] P. G. Jayathilake,et al. Muco-ciliary transport: Effect of mucus viscosity, cilia beat frequency and cilia density , 2011 .
[39] Patrick Poulin,et al. Development of a novel method for predicting human volume of distribution at steady-state of basic drugs and comparative assessment with existing methods. , 2009, Journal of pharmaceutical sciences.
[40] Denis Wirtz,et al. Micro- and macrorheology of mucus. , 2009, Advanced drug delivery reviews.
[41] Trina A. Siebert,et al. Influence of liquid-layer thickness on pulmonary surfactant spreading and collapse. , 2008, Biophysical journal.
[42] Johannes Kornhuber,et al. Quantitative modeling of selective lysosomal targeting for drug design , 2008, European Biophysics Journal.
[43] J. Widdicombe,et al. Mechanisms of Acid and Base Secretion by the Airway Epithelium , 2006, The Journal of Membrane Biology.
[44] M. Rowland,et al. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. , 2005, Journal of pharmaceutical sciences.
[45] R. Horobin,et al. A predictive model for the selective accumulation of chemicals in tumor cells , 2005, European Biophysics Journal.
[46] R. Tarran. Regulation of airway surface liquid volume and mucus transport by active ion transport. , 2004, Proceedings of the American Thoracic Society.
[47] R. Boucher,et al. Polarized distribution of HCO3− transport in human normal and cystic fibrosis nasal epithelia , 2003, The Journal of physiology.
[48] M. Andersen,et al. PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING OF STYRENE AND STYRENE OXIDE RESPIRATORY-TRACT DOSIMETRY IN RODENTS AND HUMANS , 2002, Inhalation toxicology.
[49] M. Delp,et al. Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.
[50] T. Speed,et al. Alveolar lining layer is thin and continuous: low-temperature scanning electron microscopy of rat lung. , 1995, Journal of applied physiology.
[51] B. Asgharian,et al. A multiple-path model of particle deposition in the rat lung. , 1995, Fundamental and applied toxicology : official journal of the Society of Toxicology.
[52] D. Cutler,et al. Kinetics of chloroquine uptake into isolated rat hepatocytes. , 1993, Journal of pharmaceutical sciences.
[53] W. Kreyling,et al. Intraphagolysosomal pH in canine and rat alveolar macrophages: flow cytometric measurements. , 1992, Environmental health perspectives.
[54] R. Day,et al. Bioavailability of hydroxychloroquine tablets in healthy volunteers. , 1989, British journal of clinical pharmacology.
[55] R. Day,et al. A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers. , 1988, British journal of clinical pharmacology.
[56] G. Alván,et al. The disposition of chloroquine in healthy Nigerians after single intravenous and oral doses. , 1987, British journal of clinical pharmacology.
[57] B. Beermann,et al. Disposition of chloroquine in man after single intravenous and oral doses. , 1983, British journal of clinical pharmacology.
[58] Everett Ed,et al. Endobronchial pH. Relevance of aminoglycoside activity in gram-negative bacillary pneumonia. , 1983 .
[59] L. Salako,et al. Tissue and blood concentrations of chloroquine following chronic administration in the rat , 1982, The Journal of pharmacy and pharmacology.
[60] L. Salako,et al. Kinetics of the distribution and elimination of chloroquine in the rat. , 1982, General pharmacology.
[61] M. Frisk‐Holmberg,et al. Chloroquine serum concentration and side effects: Evidence for dose‐dependent kinetics , 1979, Clinical pharmacology and therapeutics.
[62] B Poole,et al. Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. , 1978, Proceedings of the National Academy of Sciences of the United States of America.
[63] D. Reijngoud,et al. Chloroquine accumulation in isolated rat liver lysosomes , 1976, FEBS letters.
[64] Walter Hayduk,et al. Prediction of diffusion coefficients for nonelectrolytes in dilute aqueous solutions , 1974 .